Living related and living unrelated kidney transplantations: A systematic review and meta-analysis

Table 3 The characteristics of included study which reported related vs unrelated living kidney transplantation outcomes

Ref.	Number	Mean follow up (mo)	Recipient mean age (yr)	Recipient sex M/F	Immunosuppression regimen	One year graft survival rate	five years graft survival rate	10 yr graft survival rate	Acute rejection rate	Mean serum Cr at 1 yr	Mean serum Cr at final follow up	Post-transplant infectious complications
Cortesini et al[9], 2002	302 vs 172	42	32.8 ± 7.3 vs 44 ± 9.9	215/87 vs 133/39	Cyclosporine	275 (91) vs 150 (87)	232 (77) vs 136 (79)	199 (66) vs 118 (69)	N/D	1.9 ± 0.8 vs 2.0 ± 0.8	2.0 ± 0.8 vs 1.9 ± 0.8	N/D
Simforoosh et al[5], 2016	411 vs 3305	N/D	27.6 ± 10.1 vs 35.6 ± 15.6	270/138 vs 2164/1136	Cyclosporine	89% vs 90%	288 (70.2) vs 2697 (81.6)	225 (54.9) vs 2350 (71.1)	N/D	N/D	N/D	N/D
Voiculescu et al[10], 2003	38 vs 24	19.6 ± 15.4	37.7 ± 12.1 vs 53.6 ± 7.8	26/12 vs 14/10	Steroids, cyclosporine, mycophenolate mofetil	36 (94.8) vs 24 (100)	N/D	N/D	20 (52.5) vs 13 (54.2)	N/D	1.76 ±0.6 vs 1.62 ±0.5	25 (66.7) vs 9 (36.4)
Ahmad et al[15], 2008	261 vs 61	45	28 ± 16 vs 48 ± 12	N/D	Cyclosporine	247 (94.8) vs 60 (98.4)	N/D	N/D	107 (41) vs 21 (35)	N/D	N/D	N/D
Kizilisik et al[11], 2004	85 vs 24	36	N/D	N/D	Cyclosporine, azathioprine, steroid, tacrolimus, mycofenolatemofetil	81 (95) vs 23 (95.8)	75(88.3) vs 21 (87.5)	N/D	11(13) vs 5 (20)	N/D	N/D	7 (8.3) vs 8 (3.5)
Park et al[12], 2004	36 vs 41	N/D	33.6 vs 38.3	21/15 vs 28/13	Cyclosporine, steroid and mycophenolatemofetil	N/D	30 (84) vs 36 (88.5)	28 (78.8) vs 41 (74.7)	11 (30) vs 13 (31)	N/D	N/D	N/D
Wolters et al[13], 2005	66 vs 29	35	31 ± 12.5 vs 51 ± 8.5	41/25 vs 23/6	Cyclosporine/MMF/prednisone vs MMF/prednisone	N/D	62 (94.7) vs 23 (94.7)	N/D	6 (9) vs 5 (17.2)	N/D	N/D	N/D
Simforoosh et al[14], 2006	374 vs 1760	45.68 ± 46.80	28.97 ± 9.58 vs 33.46 ± 14.61	N/D	Cyclosporine, azathioprine, and prednisone	342 (91.6) vs 1610 (91.5)	286 (76.4) vs 1432 (81.4)	241 (64.4) vs 1200 (68.2)	N/D	N/D	N/D	N/D
Ishikawa et al[16], 2012	66 vs 44	12	36.1 ± 12.4 vs 55.0 ± 8.8	29/15 vs 38/28	Plasmaphresis, tacro, celecpt, Basiliximab, rituximab, methyl prednisolone, cyclosporine, deoxypergualin	65 (98.5) vs 43 (97.7)	N/D	N/D	16 (24.2) vs 14 (31.8)	N/D	N/D	N/D
Santori et al[17], 2012	111 vs 24	128.17 ± 86.64 vs 103.53 ± 86.85	26.94 ± 13.51 vs 50.04 ± 8.86	78/33 vs 18/6	Cyclosporine, tacro, steroids, celecept	N/D	N/D	71 (63.8) vs 21 (87.8)	N/D	N/D	N/D	N/D
Matter et al[18], 2016	2075 vs 410	7.72 ± 6.15	28.8 ± 9.8 vs 34.8 ± 11.1	1554/521 vs 297/113	Steroid- Azathioprine or MMF	2012 (97) vs 389 (95)	1784 (86) vs 340 (83)	1660 (67) vs 270 (66)	71 (3.4) vs 26 (6.3)	1.38 ± 0.69 vs 1.35 ± 0.61	1.71 ± 1.04 vs 1.59 ± 0.89	N/D
Ali et al[19]	92 vs 143	5	N/D	N/D	Methyl prednisolone, Cyclosporine or tacrolimus MMF	90 (97) vs 141 (98.6)	80 (86) vs 125 (87.4)	N/D	N/D	N/D	N/D	N/D

Data is presented as n (%) and Mean ± SD. N/D: Not determined; MMF: Mycophenolatemofetil.